|
US4452773A
(en)
|
1982-04-05 |
1984-06-05 |
Canadian Patents And Development Limited |
Magnetic iron-dextran microspheres
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US4795698A
(en)
|
1985-10-04 |
1989-01-03 |
Immunicon Corporation |
Magnetic-polymer particles
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
ES2067018T3
(es)
|
1988-12-28 |
1995-03-16 |
Stefan Miltenyi |
Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
|
|
US5200084A
(en)
|
1990-09-26 |
1993-04-06 |
Immunicon Corporation |
Apparatus and methods for magnetic separation
|
|
CA2096222C
(en)
|
1990-11-13 |
1998-12-29 |
Stephen D. Lupton |
Bifunctional selectable fusion genes
|
|
WO1994028143A1
(en)
|
1993-05-21 |
1994-12-08 |
Targeted Genetics Corporation |
Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
|
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
|
WO1996013593A2
(en)
|
1994-10-26 |
1996-05-09 |
Procept, Inc. |
Soluble single chain t cell receptors
|
|
WO1996018105A1
(en)
|
1994-12-06 |
1996-06-13 |
The President And Fellows Of Harvard College |
Single chain t-cell receptor
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
WO1999018129A1
(en)
|
1997-10-02 |
1999-04-15 |
Sunol Molecular Corporation |
Soluble single-chain t-cell receptor proteins
|
|
WO1999060120A2
(en)
|
1998-05-19 |
1999-11-25 |
Avidex Limited |
Soluble t cell receptor
|
|
JP2002524081A
(ja)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
前立腺−特異的膜抗原に特異的な融合受容体およびその使用
|
|
WO2000023573A2
(en)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
|
US20020131960A1
(en)
|
2000-06-02 |
2002-09-19 |
Michel Sadelain |
Artificial antigen presenting cells and methods of use thereof
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
AU2002321581C1
(en)
|
2001-08-31 |
2008-09-18 |
Adaptimmune Limited |
Soluble T cell receptor
|
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
AU2003271904B2
(en)
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
KR100872204B1
(ko)
|
2003-10-15 |
2008-12-09 |
오에스아이 파마슈티컬스, 인코포레이티드 |
이미다조피라진 티로신 키나제 억제제
|
|
US8361794B2
(en)
|
2004-06-29 |
2013-01-29 |
Immunocore Limited |
Cells expressing a modified T cell receptor
|
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
|
CA2591413A1
(en)
|
2004-12-16 |
2006-06-22 |
Vertex Pharmaceuticals Incorporated |
Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
GB0624689D0
(en)
|
2006-12-11 |
2007-01-17 |
Glaxo Group Ltd |
Novel fluorescent kinase ligands and methods employing the same
|
|
IL295053A
(en)
|
2007-03-28 |
2022-09-01 |
Pharmacyclics Llc |
Broton tyrosine kinase inhibitors
|
|
CA2682527C
(en)
|
2007-03-30 |
2017-07-11 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
CN105367503A
(zh)
|
2007-10-19 |
2016-03-02 |
阿维拉制药公司 |
杂芳基化合物和其用途
|
|
WO2009072003A2
(en)
|
2007-12-07 |
2009-06-11 |
Miltenyi Biotec Gmbh |
Sample processing system and methods
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
WO2009124119A2
(en)
|
2008-04-01 |
2009-10-08 |
The Trustes of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
TWI546290B
(zh)
|
2008-06-27 |
2016-08-21 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
ES2660418T3
(es)
|
2008-07-16 |
2018-03-22 |
Pharmacyclics Llc |
Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
|
|
EP4032552B1
(en)
|
2008-08-26 |
2023-10-04 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
PT3330293T
(pt)
|
2008-11-07 |
2019-10-18 |
Amgen Res Munich Gmbh |
Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19
|
|
US8299077B2
(en)
|
2009-03-02 |
2012-10-30 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
PT2473049T
(pt)
|
2009-09-04 |
2019-03-04 |
Sunesis Pharmaceuticals Inc |
Inibidores de tirosina quinase de bruton
|
|
CA2777053A1
(en)
|
2009-10-06 |
2011-04-14 |
The Board Of Trustees Of The University Of Illinois |
Human single-chain t cell receptors
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
DK2496698T3
(en)
|
2009-11-03 |
2019-04-15 |
Hope City |
TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
|
|
BR112012030711B1
(pt)
|
2010-05-31 |
2020-10-13 |
Ono Pharmaceutical Co. Ltd |
derivado de purinona
|
|
CN107898791A
(zh)
|
2010-06-03 |
2018-04-13 |
药品循环有限责任公司 |
布鲁顿酪氨酸激酶(btk)抑制剂的应用
|
|
PT2585470T
(pt)
|
2010-06-23 |
2017-03-06 |
Hanmi Science Co Ltd |
Novos derivados fundidos de pirimidina para inibição da actividade da tirosina cinase
|
|
CN105566229A
(zh)
|
2010-08-10 |
2016-05-11 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐及其用途和制备方法
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CN110200997A
(zh)
|
2011-03-23 |
2019-09-06 |
弗雷德哈钦森癌症研究中心 |
用于细胞免疫治疗的方法和组合物
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN103073508B
(zh)
|
2011-10-25 |
2016-06-01 |
北京大学深圳研究生院 |
激酶抑制剂及治疗相关疾病的方法
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
MX2014005289A
(es)
|
2011-11-03 |
2014-05-30 |
Hoffmann La Roche |
Compuestos de piperazina alquilados.
|
|
KR102134932B1
(ko)
|
2011-11-11 |
2020-07-17 |
프레드 헛친슨 켄서 리서치 센터 |
암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
|
|
DK2786996T3
(en)
|
2011-11-29 |
2016-12-19 |
Ono Pharmaceutical Co |
Hydrochloride PURINONDERIVAT
|
|
KR20130076046A
(ko)
|
2011-12-28 |
2013-07-08 |
한미약품 주식회사 |
타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
|
|
JP5985658B2
(ja)
|
2012-01-31 |
2016-09-06 |
ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． |
ブルトンチロシンキナーゼ阻害薬としての環状分子
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
SG10201609210SA
(en)
|
2012-05-03 |
2016-12-29 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
|
US9662343B2
(en)
*
|
2012-05-14 |
2017-05-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
LT4461308T
(lt)
|
2012-07-13 |
2025-06-10 |
The Trustees Of The University Of Pennsylvania |
Car priešnavikinio aktyvumo toksiškumo valdymas
|
|
CA2881981A1
(en)
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
AU2013327136A1
(en)
|
2012-10-02 |
2015-04-16 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
CN104822705B
(zh)
|
2012-10-24 |
2019-07-12 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
|
SG11201503459SA
(en)
|
2012-11-02 |
2015-06-29 |
Pharmacyclics Inc |
Tec family kinase inhibitor adjuvant therapy
|
|
JP6178861B2
(ja)
|
2012-11-02 |
2017-08-09 |
ファイザー・インク |
ブルトン型チロシンキナーゼ阻害剤
|
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
|
DE112012007250B4
(de)
|
2012-12-20 |
2024-10-24 |
Mitsubishi Electric Corp. |
Fahrzeuginterne Vorrichtung und Programm
|
|
BR112015015477B1
(pt)
|
2012-12-28 |
2022-07-12 |
Crystalgenomics, Inc |
Derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
|
|
WO2014153114A1
(en)
|
2013-03-14 |
2014-09-25 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CN104177338B
(zh)
|
2013-05-22 |
2018-04-03 |
南京勇山生物科技有限公司 |
一类布鲁顿激酶抑制剂
|
|
TWI648272B
(zh)
|
2013-06-25 |
2019-01-21 |
美商必治妥美雅史谷比公司 |
經取代之四氫咔唑及咔唑甲醯胺化合物
|
|
US9108442B2
(en)
|
2013-08-20 |
2015-08-18 |
Ricoh Company, Ltd. |
Image forming apparatus
|
|
CA2925124A1
(en)
|
2013-09-30 |
2015-04-02 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
WO2015057992A1
(en)
*
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
|
WO2015084892A1
(en)
|
2013-12-02 |
2015-06-11 |
Cornell University |
Methods for treating b cell proliferative disorders
|
|
WO2015082499A2
(en)
|
2013-12-03 |
2015-06-11 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
EA201691169A1
(ru)
*
|
2013-12-05 |
2016-09-30 |
Асерта Фарма Б.В. |
Терапевтическая комбинация ингибитора pi3k и ингибитора btk
|
|
PT3107544T
(pt)
|
2014-02-21 |
2021-01-05 |
Principia Biopharma Inc |
Sais e forma sólida de um inibidor de btk
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
JP6528779B2
(ja)
|
2014-03-25 |
2019-06-12 |
小野薬品工業株式会社 |
びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
CA2945320A1
(en)
|
2014-04-10 |
2015-10-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Drug regulated transgene expression
|
|
CN105017256A
(zh)
|
2014-04-29 |
2015-11-04 |
浙江导明医药科技有限公司 |
多氟化合物作为布鲁顿酪氨酸激酶抑制剂
|
|
CN105085474B
(zh)
|
2014-05-07 |
2018-05-18 |
北京赛林泰医药技术有限公司 |
鲁顿酪氨酸激酶抑制剂
|
|
CN104829610B
(zh)
|
2014-06-20 |
2017-03-15 |
中国科学院合肥物质科学研究院 |
一种新型布鲁顿酪氨酸激酶抑制剂
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
AR101476A1
(es)
*
|
2014-08-07 |
2016-12-21 |
Acerta Pharma Bv |
Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
|
|
MA40596B1
(fr)
|
2014-08-11 |
2021-12-31 |
Acerta Pharma Bv |
Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
|
|
CN105884747B
(zh)
|
2014-08-28 |
2021-01-05 |
首药控股(北京)有限公司 |
一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
|
|
CN105399756B
(zh)
|
2014-09-05 |
2019-06-25 |
广东东阳光药业有限公司 |
Btk抑制剂及其用途
|
|
CN105153154A
(zh)
|
2014-09-26 |
2015-12-16 |
广东东阳光药业有限公司 |
Btk抑制剂及其用途
|
|
CN105837576B
(zh)
|
2015-01-14 |
2019-03-26 |
湖北生物医药产业技术研究院有限公司 |
Btk抑制剂
|
|
US9278919B1
(en)
|
2015-03-13 |
2016-03-08 |
Yong Xu |
Synthesis of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
CN104844573A
(zh)
|
2015-04-17 |
2015-08-19 |
中国药科大学 |
嘧啶类btk抑制剂、其制备方法及医药用途
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
ES2980794T3
(es)
|
2015-09-15 |
2024-10-03 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
|
|
EA201891641A1
(ru)
|
2016-01-21 |
2019-01-31 |
Пфайзер Инк. |
Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
|
|
CN105732638B
(zh)
|
2016-01-22 |
2018-01-30 |
成都倍特药业有限公司 |
一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
|
ES2925644T3
(es)
|
2016-10-04 |
2022-10-19 |
Prec Biosciences Inc |
Dominios coestimuladores para su uso en células modificadas genéticamente
|
|
AU2017355544A1
(en)
|
2016-11-03 |
2019-05-16 |
Juno Therapeutics, Inc. |
Combination therapy of a T cell therapy and a BTK inhibitor
|
|
US12163952B2
(en)
|
2017-02-27 |
2024-12-10 |
Juno Therapeutics, Inc. |
Determining toxicity risk in CAR T-cell therapy
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
WO2018208849A1
(en)
|
2017-05-09 |
2018-11-15 |
Bellicum Pharmaceuticals, Inc. |
Methods to augment or alter signal transduction
|
|
CA3248436A1
(en)
|
2017-09-01 |
2025-02-21 |
Lonza Walkersville, Inc. |
END-TO-END AUTOMATION OF CELL THERAPY
|
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
|
|
US20210198372A1
(en)
|
2017-12-01 |
2021-07-01 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
US20210121466A1
(en)
|
2018-05-03 |
2021-04-29 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210223248A1
(en)
|
2018-06-01 |
2021-07-22 |
Fred Hutchinson Cancer Research Center |
Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
|
|
PL3886894T3
(pl)
|
2018-11-30 |
2024-07-01 |
Juno Therapeutics, Inc. |
Metody dawkowania i leczenia nowotworów b-komórkowych w adoptywnej terapii komórkowej
|
|
IL292665B2
(en)
|
2019-11-06 |
2026-02-01 |
Kite Pharma Inc |
Chimeric antigen receptor T cell therapy
|